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Several field studies have reported an inverse relationship between the prevalence of helminth infections and that of allergic
sensitisation/atopy. Recent studies show that immune responses induced by helminth parasites are, to an extent, comparable
to allergic sensitisation. However, helminth products induce regulatory responses capable of inhibiting not only antiparasite
immune responses, but also allergic sensitisation. The relative eﬀects of this immunomodulation on the development of protective
schistosome-specific responses in humans has yet to be demonstrated at population level, and the clinical significance of
immunomodulation of allergic disease is still controversial. Nonetheless, similarities in immune responses against helminths
and allergens pose interesting mechanistic and evolutionary questions. This paper examines the epidemiology, biology and
immunology of allergic sensitisation/atopy, and schistosome infection in human populations.
1. Introduction
The major human helminth parasites belong to two phyla,
the nematodes (or roundworms) which include intestinal
soil transmitted helminths (STH) and filarial worms (which
cause lymphatic filariasis and onchocerciasis), and the
platyhelminths (or flatworms) which include the flukes (or
trematodes, including schistosomes) and the tapeworms (or
cestodes). Although common inmost parts of the world sixty
years ago [1], these parasites are currently mainly prevalent
in sub-Saharan Africa, Asia, and South America [2–4], where
they are responsible for considerable disabilities including
blindness and elephantiasis (filarial worms). Furthermore,
helminth infections are responsible for morbidities that
include anaemia, stunted growth, poor cognitive develop-
ment, and malnutrition [5–7], hence exert a negative socioe-
conomic impact in some of the poorest communities in the
world.
Immune-mediated diseases including auto-immune dis-
eases (such as type 1 diabetes, inflammatory bowel diseases,
and rheumatoid arthritis) and allergic diseases (such as
asthma, allergic rhinitis, and atopic eczema) are reported
to be more prevalent in developed countries and in urban
areas of developing countries [8, 9]. But studies from Africa
are demonstrating that allergic diseases are common, if not
acknowledged, clinical problems in this region [10]. Immune
disorders have been responsible for increased mortality and
morbidity worldwide [11–13] and they negatively impact
on economic growth due to their elevated cost of their
treatment [14, 15]. There is also mounting evidence that
allergic disorders, especially allergic rhinitis, are associated
with attention deficit disorder and hyperactivity in children
[16, 17].
Increasing rates of childhood allergies have long been a
puzzle to epidemiologists [18, 19]. Thus, studying cohorts
of children born in 1946, 1958, and 1970, concluded that
a “new environmental agent,” contained in breast milk and
possibly infants’ food was responsible for the increase in
eczema. Emmanuel, reviewing medical literature published
from 1820 to 1900, suggested that the hay fever “epidemic”
was associated with the rapid industrial growth of the 19th
century since this disorder was rarely described prior that
period [19]. It was Strachan who in 1989, observing that
the rate of hay fever and eczema was consistently negatively
associated with family size and birth position in house-
holds, hypothesized that reduced exposure to childhood
infections due to increased hygiene was responsible for the
allergy epidemics. This hypothesis, currently referred to as
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Table 1: Heterogeneity in studies investigating the eﬀect of helminth infection on atopy.
Parasite spp, References Atopy outcome Association Population age
Ascaris lumbrocoides
[37]1 Wheeze, SPT Negative 1–4 years
[38]2 IgE, PK Negative 5–15 years
[39]1 SPT, airway responsiveness Positive 8–18 years
[40]2 Allergen-induced Th2 cytokines None 7–13 years
[41]2 SPT, wheeze None 9 years mean age
[42]2 SPT Negative 6–17 years
Wheeze, eczema, EIB None
Trichuris trichiura
[38]2 IgE, PK Negative 5–15 years
[37]1 Wheeze, SPT None 1–4 years
[43]# SPT Negative 2–8 years
Hookworm
[37]1 Wheeze, SPT None 1–4 years
[42]2 SPT Negative 6–17 years
wheeze, eczema, EIB None
Schistosoma mansoni
[44]1 SPT, IgE Negative 18± 9.7 years
[45]# SPT, asthma symptoms Negative 15 years mean age
Schistosoma haematobium
[46]1 SPT Negative 5–14 years
Cross-sectional 1 and treatment followup 2 studies are reported here.
#Longitudinal approach but treatment intervention was not the primary objective of the study. SPT: skin prick test; PK: Prausnitz-Kustner passive transfer
test, EIB: exercise-induced bronchoconstriction.
the “hygiene hypothesis,” was subsequently supported by
some epidemiological studies [20, 21] but contradicted by
others [22, 23] (see summary in Table 1). In a retrospective
case control study on Italian military cadets, Matricardi
and colleagues were able to show that cumulative exposures
to foodborne and oral-faecal infections, but not infections
transmitted via other routes, were associated with a reduced
risk of being atopic [24]. They suggested that the mode of
transmission of the pathogen was a determining factor in
subsequent protection (or lack of protection) against atopy
and asthma, hence explaining inconsistencies in previous
studies.
2. Global Burden of Schistosomiasis and Atopy
2.1. Schistosomiasis. Schistosomiasis accounts for up to 70
million DALYs annually [6], with an estimated 15,000 deaths
[4], and children carry the heaviest burden of infection [47].
With these figures, schistosomiasis is classified second only to
malaria in terms of human morbidity and mortality due to
parasitic diseases [48]. Schistosomiasis is caused by infection
with blood-dwelling trematodes of the genus Schistosoma, of
which S. haematobium, S. mansoni, and S. japonicum are the
main human schistosomes [49]. It is typically prevalent in
rural areas where natural streams, ponds, rivers, and lakes
harbouring the infected intermediate host snails, are the
main sources of water for domestic or occupational purposes
such as washing and fishing. School children usually become
infected during swimming or collecting water, while younger
children and infants become infected when accompanying
adults (washing clothes or collecting water) or by being
bathed in these water sources [50].
2.2. Atopy. Rising rates of atopic diseases have been reported
in developed countries since the end of World War II [18]
and currently constitute a major public health issue [51].
Demographic data in the US have shown an average increase
in childhood asthma prevalence of 4.3% per year from 1980
to 1996, with associated deaths and hospitalisation increasing
by 3.4% and 1.4%, respectively [52]. In the United Kingdom,
according to the British Allergy Foundation, 1 in 3 people
suﬀer from allergy at some time in their lives. This report
indicates that 58% of allergic sensitisations are triggered by
house dust mites (HDM), a known risk factor for developing
asthma and allergic rhinitis [53, 54]. Increasing prevalence
of asthma in adults over a period of 10 years and doubling in
school children over 20 years have been reported in Australia
[55]. A recent study involving 12 European countries and 19
centres reported incidences of asthma between 5 and 17%
(average 8%), while allergic rhinitis varies between 23 and
44%, with an average of 30% [56].
In less aﬄuent countries, comparable rates of atopic
diseases are generally reported in urban and suburban areas.
Thus, a prevalence of asthma of 9% was reported in urban
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areas of Rwanda [57] while the International Study of
Asthma and Allergies in childhood (ISAAC) reported an
overall prevalence of 10.9% across 22 centres in Africa [58].
Reported incidences of allergic rhinitis range from 14% to
54% in urban and suburban areas across African countries
(reviewed by [59]). Importantly, according to the ISAAC
phase three, although the prevalence was generally lower,
there were more severe symptoms of rhinoconjnnctivitis
reported in urban centres of developing countries compared
to those reported in developed countries [8]. However,
studies from Africa suggest that allergic conditions may be
underdiagnosed in Africa due to “inappropriate” diagnostic
tests and these studies call for component-resolved allergy
testing in Africa [60]. Indeed a recent study in Zimbabwe
showed that schistosome-infection resulted in impaired
diagnosis of cat allergy [61].
3. Atopy and Schistosome Life-Cycle Stages
In schistosome infection, the human immune system is
exposed to schistosome larvae (cercariae and schistosomula),
adult worm, and egg antigens. Animal studies as well as
in vitro studies have demonstrated immunological changes
and regulatory mechanisms associated with these diﬀerent
life-cycle stages. The surface of cercariae (enriched in car-
bohydrates [62]) and the newly transformed schistosomula
activate the complement cascade [63, 64] and eliciting proin-
flammatory responses [65, 66]. An excessive immunological
reaction to skin stage cercarial antigens results in cercarial
dermatitis or swimmer’s itch [67], an allergic condition
also occurring in contact with nonhuman schistosomes
that is prevalent in developed countries [68–70]. This
inflammatory reaction is rarely reported in populations in
which schistosomiasis is endemic, possibly due to regulatory
responses resulting from multiple exposures as has been
demonstrated in mice [71]. Such regulatory responses may
be induced by skin-stage schistosomula-derived molecules
such as prostaglandin E2(PGE2) which upregulates IL-10
production during skin penetration by the parasite [72].
The PGE2 is also secreted by the lung-stage schistosomula
during migration through the capillary beds of the lungs,
and this is thought to diminish eosinophil infiltrates around
the parasites (and thus inflammation [73]). In addition,
these parasites are capable of inhibiting the expression
of endothelial adhesion molecules such as E-selectin and
VCAM-1, limiting leucocyte recruitment in the lungs [74].
These anti-inflammatory mechanisms in the lungs have
been suggested as potential explanations for reduced severity
of asthma symptoms in schistosome-infected asthmatic
patients [45], although there are nomechanistic studies from
human populations to support this.
Schistosome eggs are major Th2 triggers as demonstrated
in murine studies [75, 76], and they induce formation of
fibrotic lesions or granulomas [77–79]. Indeed, an S. mansoni
egg-secreted glycoprotein, omega-1, has recently been identi-
fied that conditions dendritic cells for Th2 polarisation [25].
However, egg secretions are capable of inhibiting the specific
binding of chemokines such as CXCL8 (IL-8) and CCL3
(MIP-1α), therefore blocking chemokine-elicited migration
of neutrophils and macrophages respectively during granu-
loma formation [80].
Schistosome adult worm antigens also induce Th2
responses and IgE in mice [81], baboons [82], and humans
[83]. However, this parasite life stage elicits high levels
of modulatory responses capable of inhibiting antiparasite
[84] as well as allergic reactions [85]. The latter study
demonstrated that worm infection induces IL-10, producing
B cells that could protect mice against anaphylaxis. They
later demonstrated that egg-laying worms exacerbate while
single sex worms (precluding egg production) inhibit airway
hyperresponsiveness [86].
Together, these studies show that the diﬀerent parasite
life-cycle stages are associated with diﬀerent mechanisms of
regulation and inflammation. Although concurrent exposure
to all or most antigens is likely in endemic areas, and
despite the fact that they may induce cross-reactive immune
responses [87], the diﬀerent parasite life-cycle stages may
diﬀerentially aﬀect atopic responses.
4. Epidemiology
4.1. Schistosomiasis. The epidemiological patterns of schisto-
somiasis diﬀer from those of atopy, mainly because of their
aetiology. Indeed, while schistosome infection is acquired as
a result of exposure to parasites, atopy is a genetic predis-
position (although the clinical manifestations are influenced
by environmental factors). In schistosome endemic areas,
infection levels follow a convex shape with host age, where
infection intensity rises to peak in childhood-adolescence
and decline in adulthood [88]. This peak was initially inter-
preted as arising from diﬀerent water contact levels between
age groups [89]. However, longitudinal studies showed that
with the same exposure rate, “resistant” individuals were
older than “susceptible” individuals [90–92], suggesting
an age-dependent acquired resistance to reinfection. In
addition, in communities of diﬀerent parasite transmission,
infection intensity peaks at a younger age in areas of high
transmission compared to low-transmission areas [88, 93–
95], a phenomenon referred to as a “peak shift.” This phe-
nomenon has been interpreted as reflecting diﬀerent rates
of development of acquired resistance to infection during
schistosome infection as has been reported for Plasmodium
infections (which cause malaria) [96, 97]. This interpretation
is supported by age-related changes in immune responses,
with the peak of antibodies and cytokine associated with
protection coinciding with the decline in infection levels have
been reported in S. haematobium endemic areas [83, 98, 99].
More recently, Black and colleagues observed that the rate of
acquisition of antischistosome protective responses by adults
occupationally exposed to S. mansoni, following treatment,
is dependent on their history of exposure, being faster in
those with a longer history [100]. This study, consistent with
earlier studies [101, 102], demonstrated that resistance to
schistosome infection/reinfection is acquired independent of
age related physiological changes [103].
4.2. Atopic Diseases. Atopy is the genetic predisposition to
become excessively sensitised and produce high levels of
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IgE [104]. However, atopic diseases result from a genetic
predisposition in combination with environmental stimuli
such as allergens, smoke, diet, and/or infectious agents
[105, 106]. The epidemiology of atopic diseases is complex
as some diseases may become more prominent with age
while others diminish or disappear [107]. The earliest phases
of atopic diseases usually manifest during the first five
years of life and the severity (and prevalence) of clinical
symptoms seem to increase in late childhood/adolescence
and plateau throughout adulthood [108–110] or decline for
some conditions [111, 112].
It has been suggested that a natural history of allergy
manifestations in atopic individuals involves progression
from atopic eczema (below one year of age) to asthma or
allergic rhinitis (late childhood/adolescence), a phenomenon
referred to as the “atopic/allergic march” [112]. However,
this is not always consistent as some children may develop
atopic dermatitis long after the onset of asthma [113], while
some atopic individuals may only develop one of these
conditions throughout life. Longitudinal studies indicate
that atopy in infancy predicts the occurrence and severity
of asthma [114] and bronchial hyperresponsiveness [115] in
later life. Total and allergen-specific IgE levels also seem to
increase throughout childhood in allergic individuals [116].
However, a number of events occurring in the first few
years of life and in utero are likely to influence the onset
and persistence of disease. Thus, Klinnert and colleagues
have shown that respiratory infections during the first year
of life and parenting diﬃculties (e.g., postnatal maternal
depression) were independent predictors of the onset of
asthma during early (3 years) and late (6–8 years) childhood
in children at risk [114, 117].
Microbial exposures and diet of pregnant mothers may
also alter early gene expression in neonates, influencing the
onset of allergy in childhood (see [106, 118]). Consistent
with this hypothesis is the finding that maternal exposure to
farmmilk and farm animals during pregnancy was associated
with demethylation within the FOXP3 (Treg transcription
factor) locus in cord blood and subsequent elevated levels of
regulatory T cells (Tregs) (and their suppressive activity) in
oﬀspring [119]. Murine studies have also shown that, when
exposed to a methyl rich diet during pregnancy (as may
be the case for folate supplementation in humans), foetal
DNA may undergo changes in methylation that results in
decreased gene transcription activity, leading to subsequent
enhanced development and severity of allergic diseases [120].
The study also showed that this diet-associated allergic
phenotype was transgenerationally inheritable (persistence
of high levels of IgE and eosinophilia into the F2 generation).
5. Effector Responses in Atopy and
Schistosome Infection
5.1. Immunoglobulin E. Identified in the 1960s as a “carrier
of reaginic activity” [121, 122], IgE is well known as a
central player in atopic diseases and anaphylactic reactions.
This antibody is part of a protein network involving its
3 receptors, namely, the FcεRI, the CD23 (or FcεRII) and
galectin-3 [32], all of which can be found in soluble forms
[123, 124]. The FcεRI (also termed high-aﬃnity receptor)
is mainly expressed on mast cells and basophils but also on
epidermal Langerhans cells [125] and eosinophils [126, 127].
Cross-linking of these high-aﬃnity receptors by IgE induces
activation of mast cells and basophils and their degranula-
tion. The galectin-3 receptor is expressed on neutrophils and
on trophoblast cells in placentas [128], where it is thought to
facilitate IgE transport [129]. The CD23 receptor facilitates
the transport of IgE-antigen complexes but is also involved
in the regulation of IgE synthesis [32]. Highly conserved in
mammalian lineages [130], IgE is thought to have evolved as
a first line of defence against helminth parasites.
IgE antibodies are naturally strongly regulated and have
the lowest concentrations of all antibodies in serum of
healthy nonatopic individuals [32]. Mechanisms of regula-
tion of IgE include its short half-life in serum (12 h for
murine monoclonal antibodies [131]), the poor processing
of mRNA for the membrane ε heavy chain [132], and the
negative feedback regulation by the CD23 [133]. The latter
has been a subject of investigations in terms of therapeutic
application in atopic diseases but also in autoimmune
diseases [134] and chronic lymphocytic leukaemia [135].
5.2. CD23. CD23 is the low-aﬃnity receptor for IgE and
diﬀers from the high-aﬃnity FcεRI receptor in structure
and function. Thus, while cross-linking of the latter results
in degranulation of mast cells and release of mediators,
engagement of membrane-bound CD23 suppresses the
production of IgE by B lymphocytes [33]. CD23 has long
been proposed as a natural regulator for IgE synthesis [133]
although elevated levels of CD23+ B cells have been reported
in atopic patients [136]. As initially suggested by Aubry
and colleagues [137], CD23 not only binds IgE but also
CD21, a cell-surface protein expressed on T-cell, B-cell, and
follicular dendritic cells, classically identified as a receptor for
complement proteins [138] or Epstein-Barr virus [137]. The
interaction between CD23, IgE, and CD21 may lead to either
negative or positive regulation of IgE synthesis (reviewed in
[34–36]). The binding of IgE stabilises membrane-bound
CD23 and inhibits IgE synthesis from activated B cells, while
in the absence of IgE binding, CD23 is cleaved by ADAM10
(a disintegrin and metalloprotease protein 10), and this
destabilisation enhances IgE synthesis [32]. Soluble CD23
(sCD23) fragments resulting from the cleavage can bind to
IgE with diﬀerent aﬃnities and outcomes for IgE synthesis
depending on their oligomerization state. Trimers bind IgE
with high aﬃnity and enhance IgE synthesis by their ability to
also bind the CD21 receptor while monomers bind with low
aﬃnity but do not bind CD21 and hence inhibit IgE synthesis
[36, 139].
5.3. Immunoglobulin 4. Serum IgG4 antibodies, the least
abundant among human IgG subclasses, have long been
associated with IgE-mediated diseases [140–142]. However,
rather than the cause of disease, these antibodies seem to
be involved in the regulation of IgE-induced anaphylactic
reactions [143]. IgG4 may interfere with antigen recognition
by IgE due to their similar antigenic specificity [144],
although diﬀerent epitope-binding [145]. In a process that
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involves exchange of fab molecules, IgG4 are structurally
hetero-bivalent (each heavy chain and light chain recognising
a diﬀerent epitope within a single IgG4 molecule) and often
function as monovalent [141, 146], to bring about anti-
inflammatory eﬀects [147]. The interaction between IgG4
and a given antigen results in small and non-pathological
immune complexes (since these antibodies cannot cross-
link antigens) [146]. Furthermore, in contrast to other
IgG subclasses, IgG4 cannot fix complement but inhibits
complement activation by IgG1 [148]. IgG4 antibodies, in
allergy or helminth infection, are secreted in response to high
antigen loads [141, 149, 150] but levels of the antibodies
are diﬀerentially regulated by the same cytokines [151] as
those regulating IgE, suggesting an important homeostatic
mechanism for controlling IgE-mediated responses.
6. Control of Effector Responses in Atopy and
Schistosome Infection
In addition to the cross-regulation between Th1 and Th2
[152] (and potentially other T cell subsets), there is growing
evidence that Th2 cells interact with a complex network
of other T cell subsets as well as B cells and antibodies,
naturally or during disease (atopic or infectious). Thus, it has
emerged that Tregs play an important role in the tolerance
of ubiquitous antigens and that alterations in Treg function
[153, 154] and/or the fine balance between Tregs and Th2
cells [155, 156] determines the clinical manifestation of
atopy. Indeed, in healthy (nonatopic) individuals T cell
polarization occurs in contact with environmental allergens
but higher levels of Tregs dampen the eﬀect of Th2 cells,
leading to peripheral tolerance [156]. Tregs modulate the
activity of Th2 (and Th1) cells via several mechanisms
including the secretion of anti-inflammatory cytokines such
as IL-10 and TGF-β [155, 157]. As the description and role of
other recently identified T-helper cells is clarified (e.g., Th17
cells shown to be important in nonatopic asthma) regulation
of Th2 mediated responses will also become clearer [158].
The role of cells such as the T-helper cells recently shown
to produce both IL-17 and Th2 cytokines (IL-4, IL-5, IL-
9, and IL-13) [159] in pathogenesis is currently under
intense investigation. Our own group has recently described
a role for Th17 responses in human schistosome-acquired
immunity (submitted).
IL-10 producing B cells (Bregs) are also involved in the
recruitment of Tregs, hence contributing to the regulation
of Th2 responses as demonstrated in murine models of
helminth infection (see [31]). IL-10 can inhibit eﬀector
functions of mast cells and eosinophils, and regulate the
growth of several cells including B cells, NK cells, mast cells,
and dendritic cells. Furthermore, IL-10 modulates IgE : IgG4
ratios [154] possibly by indirectly inducing the antibody
switch to IgG4 in the B-cell progeny while preventing IgE
production [160].
IgG4 may control IgE-mediated histamine release as has
been demonstrated in filarial infection [143]. Furthermore,
it has recently been shown that the binding patterns of IgG4
antibodies correspond to natural recovery from childhood
IgE-mediated milk allergy [161], suggesting their potential
protective role in atopic diseases, although this is still
controversial [141]. In addition, early observations that IgG4
antibodies were highly elevated in sera of patients receiving
allergen immunotherapy [162] have prompted the use of
IgE : IgG4 ratio as a marker for successful immunotherapy
[142, 163, 164]. In helminth infections, high IgG4 : IgE ratio
has been associated with reduced pathology while favouring
a heavy worm load [150, 165, 166]. Interestingly, IgG4 may
be one of the “regulatory antibodies” resulting from IgG
syalilation involved in the control of immune disorders [167,
168].
7. Immune Responses in Atopy
The human immune system must distinguish between a
dangerous pathogen and ubiquitous environmental allergens
and has evolved to mount appropriate defensive responses to
the first while tolerating (or ignoring) the latter. However,
a certain proportion of individuals fail to tolerate environ-
mental allergens and develop allergic diseases such as asthma,
atopic dermatitis and allergic rhinitis. These result from
excessive sensitisation to ordinary exposures to allergens
[104]. IgE antibodies are critical eﬀector molecules in the
pathogenesis of these diseases [169]. Mast cells and basophils
are coated with specific IgE antibodies and this results in
immediate hypersensitivity (release of mediators) and/or
late-phase inflammatory reaction (cytokine secretion and
recruitment of leucocytes).
In atopic individuals, allergen products (e.g., cysteine
proteases) activate epithelial cells, which produce thymic
stromal lymphopoietin (TSLP), IL-25, and IL-33 which in
turn initiate Th2 polarisation with increased production
of IL-4, IL-5, IL-9, and IL-13 cytokines [170, 171]. Th2
cytokines are involved in the class-switching to IgE as well
as the development and recruitment of basophils, mast
cells, and eosinophils (see Figure 1(c)). IgE binds to the
high-aﬃnity FcεRI receptor on mast cells, basophils, and
eosinophils which (upon exposure to allergens) results in
their activation and degranulation (via cross-linking of
allergens), with the release of preformed mediators such
as histamine, cysteinyl leukotrienes, and prostaglandin D2
[154, 172].
A complex interplay between innate and adaptive
immune responses underlies the heterogeneous characteris-
tics of atopic diseases. Thus, recruitment of eosinophils into
the lungs of asthmatics may be promoted not just by Th2
(IL-5) alone but in conjunction with natural killer T cells
(NKT) as well as CD8+ T cells (see [173]). In addition, IL-
17-producing T cells (Th17 [174]) may be involved in the
severity of asthma [175]. These promote the recruitment
and activation of neutrophils and lead to corticosteroids—
resistant asthma [175]. IL-9-producing T-cell subset (Th9),
which probably derive from Th2 cells under the influence
of TGFβ1 [176], may also be involved in the production of
IgE and mast cell recruitment in the lungs [173]. In allergic
rhinitis, mast cells accumulate in the epithelium of the nasal
mucosa where they secrete inflammatory cytokines (IL-6, IL-
8, and TNFα) in addition to Th2 cytokines [177].
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Figure 1: Possible regulatory mechanisms in helminth infections. Primary response (a) to parasite antigens involves Th2 polarization,
IgE production, and eosinophil, mast cell, and basophil activation (I), mechanisms similar to those observed in allergic sensitisation (c).
This Th2-response may be induced by parasite-secreted antigens such as the Omega-1 secreted by S. mansoni eggs [25]. However, with
increasing parasite load or chronic infection (b), regulatory B cells are activated which suppress Th2 responses (II) via IL-10 secretion
or CD23 expression [26], and/or contribute to the recruitment of Tregs [27]. Tregs (III), which may also be induced and expanded by
parasite antigens [28, 29], either induce anergic Th2 cells (expressing GITR and CTLA4) unable to progress through to eﬀector cells, or
modify downstream eﬀector functions such as B cell switch to IgG4 and/or alternative activation of macrophages, resulting in immunological
tolerance (reviewed by [30]). This immunosuppression is induced in the context of helminth infection, but may also expand to allergen-
induced inflammation (gray line), hence suppressing allergy. DC: dendritic cell; B: B cell, Eos: eosinophil; Bas: basophil; MC:mast cell; GITR:
glucocorticoid-induced TNFα-related protein; CTLA4: cytotoxic T lymphocyte antigen 4; AAM: alternatively activated macrophage; Breg:
regulatory B cell; Treg: regulatory T cell. The question mark (?) denotes lack of strong evidence. Figure adapted from [30, 31] and collated
information from the cited references.
8. Immune Responses during
Schistosome Infection
Acquired immunity to schistosome infection was first pro-
posed by Fisher in the 1930s when analysing data from
animal studies as well as those from hospital-diagnosed
S. haematobium infected people [88]. Subsequently, the
susceptibility of schistosome larvae to immune attack was
demonstrated by in vitro studies showing that sera from S.
mansoni infected individuals could damage schistosomula in
the presence of normal human peripheral blood leucocytes
[178]. This “antibody-dependent” killing was subsequently
shown to be eosinophil mediated [178, 179], and studies
on monoclonal antibodies led to the identification of IgE
antibodies with the highest cytotoxicity for the schistosomula
[180–182]. Field studies were conducted to identify antibody
responses predictive of resistance to reinfection following
chemotherapy. Hagan et al. [83] demonstrated in a multi-
variate logistic regression that reinfection with S. haemato-
bium was less likely in individuals producing high IgE levels
against the worm antigens and more likely in those produc-
ing high levels of IgG4 against the worm or egg antigens. The
role of IgE in resistance was also demonstrated by Rihet et al.
[183], who identified specific antigens (120–165KDa and
85KDa) to which IgE reacted (on immunoblots) and showed
that these antibodies, in contrast to IgM and IgG, were sig-
nificantly higher in the sera of the most resistant individuals.
This study showed that some of the immunogenic antigens
were readily accessible to IgE on living S. mansoni larvae as
they were located on the outer membrane. However, Dunne
and colleagues, working on S. mansoni as well, showed
that IgE (produced following treatment) against adult worm
antigens, particularly a 22 kDa tegumental antigen (Sm22),
but not against any other life-cycle stages, were associated
with resistance to reinfection following treatment [184].
Both antiadult worm and anti-schistosomula tegument IgE
antibodies were associated with resistance to S. mansoni
reinfection in another study in Brazil [185] while antiegg IgE
antibodies also could confer protection against S. japonicum
reinfection [186].
Collectively, these studies and several others [187–190]
have led to the conclusion that resistance to schistosome
infection/reinfection is dependent on IgE antibodies. How-
ever, data on other antibody isotypes have been reported
which correlated with resistance to infection/reinfection. For
example, IgG3 against the recombinant antigen Sh13 has
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been associated with resistance to S. haematobium infection
[191], while antiworm and cercariae IgM were significantly
higher in individuals more resistant to reinfection with S.
mansoni [185]. Furthermore, a decline in IgA together with
an increase in IgG1 were associated with resistance acquired
with host age as well as following treatment in S. haema-
tobium endemic area [192]. IgA against Sm28GST antigen
has also been associated with reduced S. mansoni fecundity
and increased host resistance to reinfection [193]. More
recently, antiworm IgE antibodies, as well as eosinophilia
and the low aﬃnity receptor for IgE (the CD23) have been
shown to correlate with resistance in individuals undergoing
multiple rounds of treatment [100, 194], again suggesting
that IgE may be directly involved in parasite killing via
antibody-dependent cellular cytotoxicity (ADCC) in vivo.
However, since schistosomula aremore susceptible to ADCC,
it is possible that adult-worm-specific antibody responses
may rather target the incoming larvae, a process termed
“concomitant immunity” (as predicted by Fisher [88]) and
well demonstrated in rhesus monkeys [195].
As initially demonstrated by in vitro studies [196–198],
ADCC is dependent on Th2 cytokines, and these have been
involved in resistance to schistosome infection. Thus, higher
ratios of IL-4/IFN-γ and IL-5/IFN-γ were produced by spe-
cific T-cell clones from S. mansoni resistant than susceptible
individuals [199] and IL-5 correlated with lower levels of
S. haematobium infection [99] and S. mansoni reinfection
after treatment [200]. Furthermore, IL-4, IL-5, and IL-10
levels were associated with resistance posttreatment while
IFN-γ was associated with susceptibility [201]. However,
significantly higher levels of IFN-γ against adult worm and
cercariae antigens by PBMCs from resistant individuals com-
pared to those from susceptible individuals [202], suggesting
that acquired resistance to human schistosomiasis cannot be
exclusively classified into a single T helper cell subset.
Cellular immune responses, although involved in resis-
tance, mediate most of schistosome-related pathology [203,
204], which can be divided into acute and chronic diseases
based on disease progression. Acute schistosomiasis is a
debilitating febrile disease which often occurs in individuals
with no experience of infection. It is characterized by
high percentage of eosinophilia, which may be reversed
by chemotherapy [205], nausea, urticaria, dry cough, and
fever [206, 207]. Anatomically, this stage is accompanied
by a dissemination of large and destructive granulomas
around the eggs [67, 208]. Chronic schistosomiasis is often
referred to as a Th2 disease and accounts for most human
immunopathologies in endemic areas [77, 204, 208–210].
As infection becomes chronic, schistosome eggs lodge in the
liver, gut (S. mansoni), or bladder (S. haematobium), and
the granulomatous response translates into extensive tissue
damage and excessive extracellular matrix protein (ECMP)
deposition, leading to fibrosis [210].
9. Immunological Interaction between
Helminth Antigens and Allergens
9.1. Helminth Infection and the “Mast Cell Saturation”
Hypothesis. The earliest protective mechanism of helminth
infection suggested was “mast cell saturation,” whereby
helminths induce high levels of nonspecific IgE that saturate
Fc receptors on mast cells, thus inhibiting hypersensitivity
reactions [211, 212]. Further supportive evidence for the
Fc saturation hypothesis came from a study showing that
histamine release of human mast cells from lung fragments
could be blocked by preexposure of these fragments to
high total IgE [213]. However, more recent studies on
basophils have shown that high levels of polyclonal IgE and
polyclonal/specific IgE ratios from filarial- and hookworm-
infected patients do not prevent antigen-induced histamine
release [214, 215]. Nevertheless, Mitre and colleagues were
able to show that extremely high ratios of polyclonal/specific
IgE, enhanced with polyclonal myeloma IgE in vitro, could
prevent histamine release [214]. Although basophils and
mast cells may be diﬀerentially regulated [216], these exper-
iments suggested that the FcεRI receptor saturation may not
be the primary mechanism by which helminths “protect”
against allergy.
9.2. Helminth Infection and Cross-Reactive IgE Responses.
Another hypothesis suggested was that helminth parasites
induce a “clinically irrelevant” allergen-specific IgE response,
which would be cross-reactive between helminths and
allergens [217]. Cross-reactive anti-tropomyosin IgE anti-
bodies between helminths and allergens have recently been
demonstrated, where monkeys infected with Loa loa (filarial
parasites) mounted an IgE cross-reacting between filarial
tropomyosin and Derp 1 allergen but not with timothy
grass [218]. Furthermore, cross-reactivity between ascaris
and mites has been reported [219]. However, field studies
report mixed results on the eﬀects of helminth infections on
allergen-specific IgE in endemic areas [220–222]. Our recent
study has demonstrated that the levels of anti-Derp1 IgE
antibodies inversely correlate with S. haematobium infection
intensity in a high schistosome infection area in Zimbabwe
[223].
9.3. Helminth-Induced Immunomodulation. Technological
and scientific advances such as genomic sequences and
proteomic approaches have generated molecular and evolu-
tionary information on the relationship between helminth
parasites and allergic reactivity. Helminth infections are
generally characterised by a Th2-polarised immune response
[25, 84, 224], which is often associated with host resistance
to infection/reinfection [30]. However, this Th2 response
is also associated with pathology [204], consistent with
the role for Th2 in allergic diseases [171]. Nevertheless,
helminth parasites are capable of modulating this response to
prolong their survival andminimize severe pathology in their
host [76, 84, 225]. This immunomodulation is thought to
aﬀect unrelated antigens such as allergens, hence dampening
the clinical manifestation of allergy. Indeed, experimental
studies have demonstrated helminth-induced suppression of
allergic responses via multiple pathways (Figure 1). However,
these observations and mechanisms remain to be rigorously
tested in humans. Furthermore, biological and evolutionary
diﬀerences in the mouse experimental host and the natural
human host must be taken into account when extrapolating
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Figure 2: Interaction between CD23 and its ligands, IgE and CD21. Binding of IgE stabilises membrane-bound CD23 and inhibits IgE
synthesis (I) from activated B cells while in the absence of IgE binding the CD23 is cleaved by ADAM10 (a disintegrin and metalloprotease
protein 10) and this destabilisation enhances IgE synthesis (II). However, soluble CD23 (sCD23) fragments resulting from the cleavage
have the ability to bind IgE with diﬀerent aﬃnities depending on their oligomerization state: trimers (III) bind IgE with high aﬃnity while
monomers (IV) bind with low aﬃnity. Trimers enhance IgE synthesis by their ability to also bind CD21 receptor (III) while monomers fail
to bind CD21 and inhibit IgE synthesis (IV) (adapted from [32–36]).
mechanistic and phenomenological results from the mouse
to the human, for example, diﬀerences in the IgE receptors
[226].
Human studies investigating the regulatory mechanisms
underlying the protective eﬀect of helminth infections on
atopy have primarily focused on IL-10. Thus, parasite-
induced IL-10 production and skin prick reactivity were
negatively associated in Ascaris lumbricoides [42] and Schisto-
soma haematobium [46] infected populations. Furthermore,
allergen-induced IL-10 was associated with reduced Th2
responses (IL-4 and IL-5) in asthmatic schistosome infected
patients [227]. More recently, it has been shown that the
frequency of PBMCs expressing cytotoxic-T-lymphocyte
antigen 4 (CTLA-4) and monocytes expressing IL-10 from
asthmatic patients infected with S. mansoni was significantly
higher compared to their asthmatic uninfected counterparts
[228]. However, a study on an Ecuadorian population
showed no association between skin prick reactivity with
either IL-10 or IL-10-producing T cells induced by Ascaris
lumbricoides [40].
The TGFβ is another cytokine involved in the modu-
lation of immune responses, and is secreted by antigen-
presenting cells (APCs) or regulatory T cells [229]. However,
there is a paucity of human studies on this cytokine in
the context of atopy and helminth infections. Interestingly,
we have observed a negative association between atopy
and the levels of soluble CD23 in S. haematobium infected
populations (Rujeni et al., manuscript in preparation). The
CD23 is the low aﬃnity receptor for IgE and is involved in the
regulation of these antibodies [35]. As illustrated in Figure 2,
the soluble CD23 can either upregulate or downregulate IgE
synthesis depending on their size and oligomerization state.
Of note, expression of this receptor has been associated with
resistance to schistosome [194] and Ascaris [230] infections
in humans, and suppressed airway allergy in helminth-
infected mice [231].
As illustrated in Figure 1, immunomodulation during
chronic helminth infection is driven by regulatory T and
B cells (Tregs and Bregs, resp.), which secrete the above
mentioned anti-inflammatory cytokines. Treg cells are either
recruited by Bregs or induced and expanded by helminth-
derived products [28]. Both T and B regulatory cells can
suppress Th2 cells thereby regulating atopy and helminth-
induced pathology [31, 232]. Indeed, a study in our lab
has shown that Treg proportions correlate with the levels of
schistosome infection in young children actively acquiring
infection [233].
Helminthmolecules have been identified from excretory-
secretory (ES) products that are associated with immunomo-
dulation during helminth infection. Thus, the ES-62 is
a phosphorylcholine-containing glycoprotein secreted by
Acanthocheilonema viteae, a rodent filarial nematode [234].
This protein presents anti-inflammatory properties and has
been successfully tested in mouse models of allergy and
autoimmune diseases [235, 236], and it is currently being
exploited as a potential therapeutic agent for inflammatory
diseases in humans [237]. The anti-inflammatory properties
of this molecule include modulation of B-cell proliferation
and cytokine production as well as hyporesponsiveness
and desensitization of mast-cell degranulation [237–240].
The interleukin-4-inducing principle from S. mansoni egg
IPSE/alpha-1, identified as one of the most abundant
proteins secreted by S. mansoni eggs [241], has also been
associated with immunomodulation, possibly by inducing
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granulomatous responses [242]. Furthermore, IPSE/alpha-
1 has been shown to induce antigen-independent IL-4
production by murine basophils in vivo [243]. The venom
allergen-like (VAL) proteins are another group of helminth
ES products involved in immunomodulation. Thus, Hewit-
son et al. have demonstrated that antibodies to these VAL
antigens are dominant in susceptible mice in an H. polygyrus
infection model [244]. Sj-VAL-1 is one of the VAL proteins
identified in S. japonicum egg ES products inducing an
antibody response during the first 6 weeks of infection in
mice [245].
10. Convergence of Allergic and
Antiparasite Responses
There is current interest in determining the common features
in the induction of immune responses by allergens and by
helminths as well as the evolutionary advantages of main-
taining allergic responses. As illustrated above, several studies
have suggested that similarities in antigens may underlie
the commonality of Th2 responses elicited by allergens and
by helminths. A recent review [246] of allergic responses
indicated that there is relatively little structural similarity
between diﬀerent allergens (e.g., house dust mite, food
allergens, and haematophagous fluids) and between allergens
and helminth parasites. Instead, this paper suggests that the
relationship between allergic and antiparasite Th2 responses
arises from a common response to diﬀerent classes of
environmental challenges which include helminth parasites,
venoms and haematophagous fluids, and environmental
irritants such as carcinogens and noxious xenobiotics, so
that this diverse group of stimuli activates responses collec-
tively known as “allergic host defences” [246]. Within this
paradigm, these environmental challenges are characterised
only by the type of response they elicit with multiple
pathways leading to the activation of Th2 responses with
the result of protecting against environmental challenges by
either reduced exposure to, or elimination of the “irritant.”
In this scenario, allergic reactivity is believed to have evolved
as an important and essential mechanism against harm
rather than a harmful overreaction of a misdirected immune
system [247]. Studies in cancer patients also show a negative
association between cancer and atopy which has led to
the suggestion that allergy protects against some types of
cancer [248, 249]. This suggests that the Th2 responses
protecting against allergens, carcinogens, and helminths are
complex. This presents a challenge for the development
of therapeutics relying on helminth products to overcome
allergic responses, since induction of allergic responses as
well as the eﬀector mechanisms maybe tightly regulated, and
the eﬀector responses they elicit may have been selected for
redundancy.
11. Conclusions
We have shown similarities in the immunological responses
to schistosome parasites and to allergens. Studies continue
to determine the aetiology of the similar responses and the
evolutionary pathways that may have led to the development
and maintenance of allergic responses which are paradoxi-
cally harmful to the host [246, 247], but may be essential to
protect against harm from environmental challenges [246].
The clinical manifestation of atopy is complex with several
studies from helminth endemic areas having shown that
allergic sensitisation and clinical manifestation of allergy
can be dissociated [222]. Furthermore, allergic disease and
parasitic infections exist as comorbidities in many patients
and are not mutually exclusive [250]. The role of impaired
serological allergy diagnosis in parasitized allergy patients
as well as under diagnosis in developing countries needs to
be addressed to inform future studies. Detailed longitudinal
and mechanistic studies relating atopy and clinical disease to
schistosome infection and disease in human populations will
be valuable to inform on not only the immunological process
occurring, but more importantly on clinical management of
allergy and schistosomiasis patients.
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